Huiming Zhang

This inventor holds 10 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 4 EPO patents. Top assignees: Eisai R&d Management Co., Ltd., Eisai Inc.. Active years: 2013-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Huiming Zhang. Retrieved from https://idiyas.com/inventor/huiming-zhang-x72ap2fq

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 10 (Patent Applications = 1)

% Patents Active = 90.0

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 5.0

ph-index = 5

Forward Citations = 83(Granted Patents)

Company Filing History:

9 out of 530

Eisai R&d Management Co., Ltd.

Years Active: 2013-2021

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11160783 - Multikinase inhibitors for use in the treatment of cancer (2021-11-02),

2. 10450324 - Methods useful in the synthesis of halichondrin B analogs (2019-10-22),

3. 10030032 - Methods useful in the synthesis of halichondrin B analogs (2018-07-24),

4. 9695188 - Methods useful in the synthesis of halichondrin B analogs (2017-07-04),

5. 9416109 - Methods and compounds useful in the synthesis of orexin-2 receptor antagonists (2016-08-16),

6. 9303039 - Methods useful in the synthesis of halichondrin B analogs (2016-04-05),

7. 8962858 - Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives (2015-02-24),

8. 8937056 - Multikinase inhibitors for use in the treatment of cancer (2015-01-20),

9. 8802871 - Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives (2014-08-12),

10. 8609640 - Multikinase inhibitors for use in the treatment of cancer (2013-12-17),

Title: Huiming Zhang: Innovator in Cancer Treatment

Introduction

Huiming Zhang is a prominent inventor based in Andover, MA (US), known for his significant contributions to the field of cancer treatment. With a total of 10 patents, he has made remarkable strides in developing innovative therapies aimed at combating various forms of cancer.

Latest Patents

Among his latest patents, Zhang has developed multikinase inhibitors for use in the treatment of cancer. This invention provides compounds, pharmaceutical compositions, and methods specifically designed for treating certain cancers. The compositions generally comprise a compound of formula (I), wherein R-Rare is defined within the patent, or pharmaceutically acceptable salts or esters thereof, along with a pharmaceutically acceptable carrier. Additionally, he has improved methods useful for the synthesis of halichondrin B analogs, such as eribulin and its pharmaceutically acceptable salts, including eribulin mesylate.

Career Highlights

Throughout his career, Huiming Zhang has worked with notable companies, including Eisai R&D Management Co., Ltd. and Eisai Inc. His work has been instrumental in advancing cancer therapies and improving patient outcomes.

Collaborations

Zhang has collaborated with esteemed colleagues, including Bryan Matthew Lewis and Yongbo Hu, contributing to the development of innovative solutions in the pharmaceutical industry.

Conclusion

Huiming Zhang's dedication to cancer research and his innovative patents highlight his role as a key figure in the fight against cancer. His work continues to inspire advancements in medical treatments and therapies.

Profile summary based on public USPTO records.